Esperion Therapeutics (ESPR) Is Surging On FDA News


Shutterstock photo

(RTTNews.com) - Esperion Therapeutics ( ESPR ) announced Monday morning that the FDA has confirmed that the company's LDL-C lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid.

Esperion Therapeutics has gapped open sharply higher this morning and is now up 10.33 at $34.00 on above average volume. The stock has jumped to a 1-week high and is challenging the highs of the year.

For comments and feedback: contact editorial@rttnews.com




This article appears in: Stocks , Stocks
Referenced Symbols: ESPR


More from RTT News

Subscribe






See headlines for ESPR

Follow on: